In particular, we found a novel glycan CRC marker Manβ1‐4GlcNAcβ, which, together with the level of IgG, IgA, and IgM, provides both high sensitivity Se = 81.8% and specificity Sp = 95.8%. Here, CD79A is linked to colorectal carcinoma.